Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels

Clinical Endocrinology

Volumn 79, Issue 6, 2013, Pages 845-852

  Ciresi, Alessandro ^a   Amato, Marco Calogero ^a   Guarnotta, Valentina ^a   Lo Castro, Flavia ^a   Giordano, Carla ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; PROLACTIN; TRIACYLGLYCEROL; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; GLUCOSE BLOOD LEVEL; LIPID;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; METABOLIC PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROLACTINOMA; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; METABOLOME; OBESITY; PATHOLOGY; PITUITARY NEOPLASMS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADIPOSITY; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLOME; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84887421467     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12204     Document Type: Article

References (41)

1. Gillam, M.P., Molitch, M.E., Lombardi, G., et al,. (2006) Advances in the treatment of prolactinomas. Endocrine Reviews, 27, 485-534. (Pubitemid 44213229)
2. Greenman, Y., Tordjman, K., &, Stern, N., (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clinical Endocrinology, 48, 547-553. (Pubitemid 28252990)
3. Biller, B.M., Baum, H.B., Rosenthal, D.I., et al,. (1992) Progressive trabecular osteopenia in women with hyperprolactinemia amenorrhea. The Journal of Clinical Endocrinology and Metabolism, 75, 692-697.
4. Naliato, E.C., Violante, A.H., Caldas, D., et al,. (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary, 11, 21-28. (Pubitemid 351168081)
5. Naliato, E.C., Violante, A.H., Caldas, D., et al,. (2007) Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clinical Endocrinology, 67, 845-852. (Pubitemid 350135126)
6. Naliato, E.C., Violante, A.H., Gaccione, M., et al,. (2008) Body fat in men with prolactinoma. Journal of Endocrinological Investigation, 31, 985-990.
7. Schmid, C., Goede, D.L., Hauser, R.S., et al,. (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Medical Weekly, 136, 254-258.
8. Melmed, S., Casanueva, F.F., Hoffman, A.R., et al,. (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 96, 273-288.
9. Yavuz, D., Deyneli, O., Akpinar, I., et al,. (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. European Journal of Endocrinology, 149, 187-193. (Pubitemid 37120990)
10. Berinder, K., Nyström, T., Höybye, C., et al,. (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary, 14, 199-207.
11. dos Santos Silva, C.M., Barbosa, F.R., Lima, G.A., et al,. (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity, 19, 800-805.
12. Amato, M.C., Giordano, C., Galia, M., et al,. (2010) Visceral Adiposity Index (VAI): a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care, 33, 920-922.
13. American Association of Clinical Endocrinologists. (2000) The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management-2000 update. Endocrine Practice, 6, 43-84.
14. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al,. (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin in man. Diabetologia, 28, 412-419. (Pubitemid 15018832)
15. Matsuda, M., &, De Fronzo, R.A., (2001) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 24, 460-464.
16. Utzschneider, K.M., Prigeon, R.L., Faulenbach, M.V., et al,. (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care, 32, 335-341.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
18. Ben-Jonathan, N., Hugo, E.R., Brandebourg, T.D., et al,. (2006) Focus on prolactin as a metabolic hormone. Trends in Endocrinology & Metabolism, 17, 110-116.
19. Landgraf, R., Landraf-Leurs, M.M., Weissmann, A., et al,. (1977) Prolactin: a diabetogenic hormone. Diabetologia, 13, 99-104. (Pubitemid 8077629)
20. Johnston, D.G., Alberti, K.G., Nattrass, M., et al,. (1980) Hyperinsulinaemia in hyperprolactinaemic women. Clinical Endocrinology, 13, 361-368. (Pubitemid 10004303)
21. Pelkonen, R., Nikkilä, E.A., &, Grahne, B., (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clinical Endocrinology, 16, 383-390. (Pubitemid 12188630)
22. Maccario, M., Grottoli, S., Razzore, P., et al,. (1996) Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. European Journal of Endocrinology, 135, 205-210. (Pubitemid 26284193)
23. Fleenor, D.E., &, Freemark, M., (2001) Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology, 142, 2805-2810. (Pubitemid 32575515)
24. Ling, C., Svensson, L., Odén, B., et al,. (2003) Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. The Journal of Clinical Endocrinology and Metabolism, 88, 1804-1808. (Pubitemid 36623408)
25. Korbonits, M., Chitnis, M.M., Gueorguiev, M., et al,. (2001) The release of leptin and its effect on hormone release from human pituitary adenomas. Pituitary, 4, 49-55.
26. Balci, H., Akgun-Dar, K., Gazioglu, N., et al,. (2009) The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. Pituitary, 12, 170-176.
27. Tchernof, A., Poehlman, E.T., &, Després, J.P., (2000) Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes & Metabolism, 26, 12-20. (Pubitemid 30146088)
28. de Assunção Alves Rodrigues, L.F., Campos, S.M., Miranda, P.A., et al,. (2012) Prolactinoma: a condition associated with hypoadiponectinemia. Hormone and Metabolic Research, 44, 832-838.
29. Tuzcu, A., Yalaki, S., Arikan, S., et al,. (2009) Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary, 12, 330-334.
30. Tuzcu, A., Bahceci, M., Dursun, M., et al,. (2003) Insulin sensitivity and hyperprolactinemia. Journal of Endocrinological Investigation, 26, 341-346. (Pubitemid 36763695)
31. Ben-Jonathan, N., &, Hnasko, R., (2001) Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews, 22, 724-763. (Pubitemid 34214293)
32. Comings, D.E., Flanagan, S.D., Dietz, G., et al,. (1993) The dopamine D2 receptor (DRD2) as a major gene in obesity and height. Biochemical Medicine and Metabolic Biology, 50, 176-185. (Pubitemid 23295784)
33. Cincotta, A.H., Meier, A.H., &, Cincotta Jr, M., (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opinion on Investigational Drugs, 8, 1683-1707. (Pubitemid 29460532)
34. Cincotta, A.H., &, Meier, A.H., (1996) Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care, 19, 667-670. (Pubitemid 26182986)
35. Kamath, V., Jones, C.N., Yip, J.C., et al,. (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care, 20, 1697-1701. (Pubitemid 27463045)
36. Pijl, H., Ohashi, S., Matsuda, M., et al,. (2000) Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care, 23, 1154-1161. (Pubitemid 30616805)
37. Doknic, M., Pekic, S., Zarkovic, M., et al,. (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. European Journal of Endocrinology, 147, 77-84. (Pubitemid 34814743)
38. Serri, O., Li, L., Mamputu, J.C., et al,. (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clinical Endocrinology, 64, 366-370.
39. Fahy, U., Hopton, M.I., Hartog, M., et al,. (1999) The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Human Reproduction, 14, 285-287. (Pubitemid 29097373)
40. Amato, M.C., Verghi, M., Galluzzo, A., et al,. (2011) The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Human Reproduction, 26, 1486-1494.
41. Ciresi, A., Amato, M.C., Pizzolanti, G., et al,. (2012) Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. The Journal of Clinical Endocrinology and Metabolism, 97, 2907-2915.